KÄÄPÄ Biotech Lands Strategic Investment to Accelerate Global Nutraceutical Expansion

KÄÄPÄ Biotech has closed a €9 million strategic investment that strengthens its position as a European leader in functional mushroom biotechnology and accelerates its expansion into the global nutraceutical market. The Finnish company has built one of the sector’s most advanced vertically integrated systems, combining indoor cultivation, proprietary extraction, and clinical validation to meet the growing demand for traceable, science-backed mushroom ingredients.

The new funding round was led by PeakBridge, the global agri-food tech fund manager within the Edmond de Rothschild Private Equity partnership, alongside specialist investor Zintinus. Their backing reflects a wider shift in the wellness and nutrition landscape, where consumers and brands are moving toward clinically supported bioactives, transparent supply chains, and dependable European manufacturing.

For KÄÄPÄ Biotech, the investment marks a decisive step in scaling its NordRelease® functional mushroom ingredients, products built on a proprietary extraction method designed to standardise bioactive levels, ensure traceability from cultivation to final ingredient, and provide consistent potency at an industrial scale. With more than 180 customers across over 20 markets, demand has now outpaced the company’s existing capacity, prompting a rapid buildout of infrastructure and production capabilities.

KÄÄPÄ Biotech

CEO and co-founder Eric Puro said the category’s momentum reflects a shift toward measurable efficacy and trust. He noted that PeakBridge’s continued support, following an initial investment earlier this year, brings deep food industry expertise and operational value. The partnership with Zintinus adds strategic insight, networks, and sector-focused experience that will help KÄÄPÄ Biotech reach new global markets.

Dr. Gali Artzi, Partner and CTO at PeakBridge, highlighted the company’s vertical integration and rigorous standardisation as critical strengths in a market long reliant on imports from Asia. He described functional mushrooms as a field where traditional use, emerging clinical research, and modern extraction technologies are converging, placing KÄÄPÄ Biotech at the forefront of its evolution.

Zintinus Partner Christian Neuss said the company’s proprietary NordRelease® process and scalable indoor cultivation platform set a new benchmark for quality and transparency. He underscored the strategic alignment between KÄÄPÄ Biotech’s approach and Zintinus’ mission to support technologies that enhance both consumer trust and environmental resilience.

The investment follows two major infrastructure expansions that have strengthened KÄÄPÄ Biotech’s European supply chain. In September 2024, the company opened a state-of-the-art cultivation facility in Paimio, Finland, significantly increasing R&D and production capacity. This was followed by a second site in Salo in June 2025, enabling further scale as the global functional mushroom market accelerates. These facilities form the backbone of KÄÄPÄ Biotech’s strategy: controlled Nordic cultivation, proprietary extraction, and full vertical ownership from mycelium to finished ingredient.

As nutraceutical companies, food and beverage brands, and wellness innovators increasingly seek clinically validated, sustainably produced bioactives, KÄÄPÄ Biotech is positioned to anchor the next generation of mushroom-derived ingredients. With new capital, expanded facilities, and growing international momentum, the company enters a critical period of scale, one where Nordic-grown, science-led functional mushrooms are poised to shape the future of global wellness.